XML 53 R43.htm IDEA: XBRL DOCUMENT
v3.20.2

Segmentation of key figures (Details 5) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 11,347 | $ 11,764 | $ 23,630 | $ 22,870
Net sales (in % of total net sales) | 100.00% | 100.00% | 100.00% | 100.00%
Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (4.00%) |  | 3.00% |
Net sales, change in %, cc | (1.00%) |  | 6.00% |
Europe [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 4,094 | $ 4,487 | $ 8,924 | $ 8,862
Net sales (in % of total net sales) | 36.00% | 38.00% | 38.00% | 39.00%
Europe [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (9.00%) |  | 1.00% |
Net sales, change in %, cc | (6.00%) |  | 4.00% |
US |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 4,023 | $ 3,978 | $ 8,135 | $ 7,561
Net sales (in % of total net sales) | 35.00% | 34.00% | 34.00% | 33.00%
US | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 1.00% |  | 8.00% |
Net sales, change in %, cc | 1.00% |  | 8.00% |
Asia/Africa/Australasia [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,464 | $ 2,439 | $ 4,976 | $ 4,774
Net sales (in % of total net sales) | 22.00% | 21.00% | 21.00% | 21.00%
Asia/Africa/Australasia [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 1.00% |  | 4.00% |
Net sales, change in %, cc | 2.00% |  | 6.00% |
Canada and Latin America [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 766 | $ 860 | $ 1,595 | $ 1,673
Net sales (in % of total net sales) | 7.00% | 7.00% | 7.00% | 7.00%
Canada and Latin America [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (11.00%) |  | (5.00%) |
Net sales, change in %, cc | 5.00% |  | 9.00% |
Established Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 8,530 | $ 8,867 | $ 17,732 | $ 17,129
Net sales (in % of total net sales) | 75.00% | 75.00% | 75.00% | 75.00%
Established Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (4.00%) |  | 4.00% |
Net sales, change in %, cc | (3.00%) |  | 5.00% |
Emerging Growth Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,817 | $ 2,897 | $ 5,898 | $ 5,741
Net sales (in % of total net sales) | 25.00% | 25.00% | 25.00% | 25.00%
Emerging Growth Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (3.00%) |  | 3.00% |
Net sales, change in %, cc | 5.00% |  | 9.00% |
Innovative Medicines |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 9,188 | $ 9,326 | $ 18,943 | $ 18,106
Net sales (in % of total net sales) | 100.00% | 100.00% | 100.00% | 100.00%
Innovative Medicines | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (1.00%) |  | 5.00% |
Net sales, change in %, cc | 1.00% |  | 7.00% |
Innovative Medicines | Europe [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,964 | $ 3,218 | $ 6,366 | $ 6,352
Net sales (in % of total net sales) | 32.00% | 35.00% | 34.00% | 35.00%
Innovative Medicines | Europe [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (8.00%) |  | 0.00% |
Net sales, change in %, cc | (5.00%) |  | 3.00% |
Innovative Medicines | US |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 3,515 | $ 3,336 | $ 7,057 | $ 6,329
Net sales (in % of total net sales) | 38.00% | 36.00% | 37.00% | 35.00%
Innovative Medicines | US | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 5.00% |  | 12.00% |
Net sales, change in %, cc | 5.00% |  | 12.00% |
Innovative Medicines | Asia/Africa/Australasia [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,123 | $ 2,106 | $ 4,301 | $ 4,123
Net sales (in % of total net sales) | 23.00% | 23.00% | 23.00% | 23.00%
Innovative Medicines | Asia/Africa/Australasia [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 1.00% |  | 4.00% |
Net sales, change in %, cc | 2.00% |  | 6.00% |
Innovative Medicines | Canada and Latin America [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 586 | $ 666 | $ 1,219 | $ 1,302
Net sales (in % of total net sales) | 7.00% | 6.00% | 6.00% | 7.00%
Innovative Medicines | Canada and Latin America [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (12.00%) |  | (6.00%) |
Net sales, change in %, cc | 5.00% |  | 8.00% |
Innovative Medicines | Established Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 6,909 | $ 7,071 | $ 14,266 | $ 13,638
Net sales (in % of total net sales) | 75.00% | 76.00% | 75.00% | 75.00%
Innovative Medicines | Established Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (2.00%) |  | 5.00% |
Net sales, change in %, cc | (2.00%) |  | 6.00% |
Innovative Medicines | Emerging Growth Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,279 | $ 2,255 | $ 4,677 | $ 4,468
Net sales (in % of total net sales) | 25.00% | 24.00% | 25.00% | 25.00%
Innovative Medicines | Emerging Growth Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 1.00% |  | 5.00% |
Net sales, change in %, cc | 9.00% |  | 11.00% |
Sandoz |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 2,159 | $ 2,438 | $ 4,687 | $ 4,764
Net sales (in % of total net sales) | 100.00% | 100.00% | 100.00% | 100.00%
Sandoz | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (11.00%) |  | (2.00%) |
Net sales, change in %, cc | (9.00%) |  | 1.00% |
Sandoz | Europe [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 1,130 | $ 1,269 | $ 2,558 | $ 2,510
Net sales (in % of total net sales) | 52.00% | 52.00% | 55.00% | 53.00%
Sandoz | Europe [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (11.00%) |  | 2.00% |
Net sales, change in %, cc | (8.00%) |  | 5.00% |
Sandoz | US |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 508 | $ 642 | $ 1,078 | $ 1,232
Net sales (in % of total net sales) | 24.00% | 26.00% | 23.00% | 26.00%
Sandoz | US | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (21.00%) |  | (12.00%) |
Net sales, change in %, cc | (21.00%) |  | (12.00%) |
Sandoz | Asia/Africa/Australasia [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 341 | $ 333 | $ 675 | $ 651
Net sales (in % of total net sales) | 16.00% | 14.00% | 14.00% | 14.00%
Sandoz | Asia/Africa/Australasia [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 2.00% |  | 4.00% |
Net sales, change in %, cc | 4.00% |  | 5.00% |
Sandoz | Canada and Latin America [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 180 | $ 194 | $ 376 | $ 371
Net sales (in % of total net sales) | 8.00% | 8.00% | 8.00% | 7.00%
Sandoz | Canada and Latin America [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (7.00%) |  | 1.00% |
Net sales, change in %, cc | 5.00% |  | 12.00% |
Sandoz | Established Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 1,621 | $ 1,796 | $ 3,466 | $ 3,491
Net sales (in % of total net sales) | 75.00% | 74.00% | 74.00% | 73.00%
Sandoz | Established Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (10.00%) |  | (1.00%) |
Net sales, change in %, cc | (9.00%) |  | 1.00% |
Sandoz | Emerging Growth Markets [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 538 | $ 642 | $ 1,221 | $ 1,273
Net sales (in % of total net sales) | 25.00% | 26.00% | 26.00% | 27.00%
Sandoz | Emerging Growth Markets [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (16.00%) |  | (4.00%) |
Net sales, change in %, cc | (9.00%) |  | 2.00% |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |